Charles Rosier's Personal Website on Strikingly
In 1996, Charles Rosier (Profil charles rosier via strikingly.com)'s job began at Lehman Brothers, just before he joined UBS Warburg Investment Bank. To get more training and to prepare for further French education, he studied for another two years. charles rosier was awarded his first scientific Baccalaureate degree, similar to A-levels in the UK.
He pursued his career of being an investment banker and switched jobs within that industry a few times. Charles Rosier began his career at Lehman Brothers in 1996 prior to joining UBS Warburg Investment Bank. Afterwards, he joined Goldman Sachs Bank, where he was put in charge of the finance department. Charles Rosier studied at Fenelon Sainte-Marie and earned his scientific degree in 1991.
Charles Rosier's Programmes on Environmental Awareness
For poor countries to have cost-effective energy solutions, MPOWERD created LED lanterns. Charles Rosier is dedicated to helping the environment by developing energy and power sectors in poor countries. He financed MPOWERD to formulate other energy solutions such as lanterns. As a result, over 25 poor countries all around the world have been supplied by MPOWERD. Charles Rosier supported Luci MPOWERD, a clean and renewable-energy solution-provider. The company was able to create innovative solutions because of the full assistance he gave.
Charles Rosier put in place five major principles (Client Focus, Global Thinking Presence, Long Term View, Meritocracy and Partnership and World-Class Governance) at BTG Pactual. He worked in the role of partner at BTG Pactual, a bank in Latin America, noted for employing 2,500 employees all around the country and having 30 years of experience in the international market. BTG Pactual is an investment bank based in Latin America, with whom Charles Rosier was a partner for years.
Charles Rosier in Supporting Health
Charles Rosier invested capital in the organisation, which allowed them to do research and give him specific profit-share. He is also one of the investors of Mapreg, a laboratory in Paris that examines depression, strokes and other serious conditions. Charles Rosier was the project’s major investor. A drug treatment for strokes that can cause spinal cord injury was being properly and intensively tested.